Trially CEO Kyle McAllister explains why transparent AI reasoning is essential for trial patient matching.
|Articles|July 1, 2007
- Applied Clinical Trials-07-01-2007
- Volume 0
- Issue 0
eShowcase: VISTA
Shorter Study Start-Up Times Targeted with Site Assessment Process Tool
Advertisement
Shorter Study Start-Up Times Targeted with Site Assessment Process Tool
Scientific Software Tools (Media, PA) has released the latest version of VISTA, its Web-based automated site technology assessment service. The new service incorporates additional features to assess for e-clinical studies.
VISTA allows qualitative surveys conducted by the investigative site-—including the technology survey—to be completed online, which eliminates paper-based surveys and manual entry into a database. Also, this Web-based process allows investigators a single point of contact for all required surveys.
VISTA presents the data obtained from the surveys and the technical assessment in XML format, which allows for easier data sharing into databases, as well as improved data sharing between different systems used by all parties involved, including clinical staff, investigators, sponsors, and others.
VISTA Plus includes additional data capture and reporting, and VISTA Services includes additional components to the basic service.
Scientific Software Tools, Inc., (610) 891-1640,
Articles in this issue
over 19 years ago
Reach Out to the Peopleover 19 years ago
A Survey of Survivorsover 19 years ago
Will the Real CRO Please Stand Upover 19 years ago
CRA: Jack of All Tradesover 19 years ago
Pediatric Policies Grow Upover 19 years ago
FDA Moves to Update Research Enterpriseover 19 years ago
Recruitment Done Rightover 19 years ago
eShowcase: iTrial EDCAdvertisement
Related to this article
Trially Co-founder and CEO Kyle McAllister, explains how AI absorbing the bulk of clinical-trial chart reviews can free research sites to focus staff time on higher-value tasks.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, explains why the shift from narrow AI tools to a continuous learning clinical operating system is where the real operational value lies—and what it takes to get there.
In this Q&A, Saamir Pasha and Carole Berini, PhD, of Ontada discuss what it takes to harmonize fragmented oncology data into reliable real-world evidence, how lab markers can proxy for missing functional status data, and where the biggest remaining barriers to consistent RWE generation lie.
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
Clinical trial endpoints define what success looks like, but patients and caregivers are rarely the ones setting that definition, and the gap between what trials measure and what patients actually value is showing up in post-approval evidence, regulatory submissions, and the design rooms where protocols are written.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection
2
What It Actually Means to Embed AI Across the Clinical Operating Model
3
FDA Launches Rare Disease Framework Initiative to Reimagine Drug Development for Small Patient Populations
4
The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
5